fda compounding semaglutide crackdown news november 2025 supply The Food and Drug Administration's on cheaper, independently produced versions FDA Crackdown on Compounded GLP-1

Without eating disorder screening, a prescriber may see a patient in a higher-weight body and recommend a GLP-1 medication without any awareness that they are treating someone in the midst of a life-threatening restrictive illness

Incretin-based therapies and diabetic retinopathy: real-world evidence in Older U.S

Site rotation is a fundamental principle of subcutaneous injection therapy

Cost and access play a role as well

Regulatory expectations, manufacturing feasibility, clinical trial design, and commercial differentiation play decisive roles in determining whether a biologically compelling peptide ultimately reaches patients

It is a repeating pattern of flare and partial resolution with each escalation step